{"id":44391,"date":"2012-05-07T11:12:47","date_gmt":"2012-05-07T11:12:47","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/assurerx-health-launches-personalized-medicine-test-for-adhd.php"},"modified":"2012-05-07T11:12:47","modified_gmt":"2012-05-07T11:12:47","slug":"assurerx-health-launches-personalized-medicine-test-for-adhd","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/assurerx-health-launches-personalized-medicine-test-for-adhd.php","title":{"rendered":"AssureRx Health Launches Personalized Medicine Test for ADHD"},"content":{"rendered":"<p><p>    MASON, Ohio, May 7, 2012 \/PRNewswire\/ --AssureRx Health,    Inc. today announced it has launched a personalized medicine    test for the growing number of children and adults diagnosed    with attention deficit hyperactivity disorder (ADHD). The new    pharmacogenomic test can assist clinicians with important    medication decisions that result from genomic differences in    how individual patients tolerate ADHD medications.  <\/p>\n<p>    GeneSightRx ADHD analyzes variations in three genes that    influence how a patient might metabolize certain medications    used to treat ADHD in children and adults. Understanding    a patient's unique genomic profile may help a clinician    individualize a patient's medication selection and avoid side    effects that often occur with these medications. The test    provides objective, evidence-based information for clinicians    to personalize medication selection for each patient.  <\/p>\n<p>    The GeneSightRx ADHD analysis is based on pharmacogenomics,    FDA-approved manufacturer's drug labels, published peer    reviewed research, and proven pharmacology. The new ADHD test    adds to the company's treatment decision support products that    include GeneSightRx Psychotropic, a psychiatric pharmacogenomic    product that tests important genomic variants affecting    metabolism to psychiatric medications for individual    patients.  <\/p>\n<p>    ADHD diagnoses increased 66 percent from 6.2 million in 2000 to    10.4 million in 2010, according to a study published in the    March\/April 2012 issue of Academic Pediatrics. ADHD is the most    common childhood disorder and can continue into adulthood.    Symptoms of ADHD include an inability to stay focused or pay    attention, difficulty controlling behavior, and hyperactivity.  <\/p>\n<p>    \"ADHD is a neurobehavioral disorder affecting millions of    children and adults. With the introduction of GeneSightRx ADHD,    clinicians now have an objective, evidence-based tool for    individualizing ADHD medications,\" said James S. Burns,    president and CEO of AssureRx Health.\"Our goal is to    build a portfolio of innovative pharmacogenomic and other    treatment decision support products to help physicians    individualize the treatment of patients with neuropsychiatric    and other disorders.\"  <\/p>\n<p>    When a clinician orders the test, a DNA sample is taken from    the patient with a simple, non-invasive cheek swab. The    specimen is sent overnight to AssureRx Health's CLIA-certified    and CAP-accredited laboratory. The ordering clinician receives    the patient report via a secure online portal that presents the    patient's genomic information in an easy-to-read and clinically    actionable format.  <\/p>\n<p>    About GeneSightRx  <\/p>\n<p>    GeneSightRx is a laboratory developed genomic test that uses    cutting edge technology to measure and analyze clinically    important genomic variants in the treatment of psychiatric    disorders. The results of the GeneSightRx report can help a    clinician understand the way a patient's unique genomic makeup    may affect certain psychiatric drugs. The analysis is based on    pharmacogenomics, the study of genomic factors that influence    an individual's response to drug treatments, FDA approved    manufacturer's drug labels, peer-reviewed scientific and    clinical publications, and proven drug pharmacology. Quick    turnaround time, combined with a customized report of the    patient's genomic makeup, clinical experience, and other    factors can help a physician make personalized drug treatment    choices for each individual patient. To learn more about    pharmacogenomics and GeneSightRx, please click here. Be sure to watch the    educational video on our YouTube channel.  <\/p>\n<p>    About AssureRx Health  <\/p>\n<p>    AssureRx Health, Inc. is a personalized medicine company that    specializes in pharmacogenomics dedicated to helping clinicians    determine the right drug for individual patients suffering from    neuropsychiatric and other disorders. The GeneSightRx analysis    is based on pharmacogenomics the study of the genomic factors    that influence an individual's response to drug treatments,    using FDA approved manufacturers' drug labels, scientific and    clinical peer-reviewed publications, and proven pharmacology.    The company was founded to commercialize industry-leading    personalized medicine technology. To learn more about    pharmacogenomics and GeneSightRx, visit <a href=\"http:\/\/www.assurerxhealth.com\" rel=\"nofollow\">http:\/\/www.assurerxhealth.com<\/a>.  <\/p>\n<\/p>\n<p>Originally posted here: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/assurerx-health-launches-personalized-medicine-110000491.html;_ylt=A2KJjaglrqdP0igAI.T_wgt.\" title=\"AssureRx Health Launches Personalized Medicine Test for ADHD\">AssureRx Health Launches Personalized Medicine Test for ADHD<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> MASON, Ohio, May 7, 2012 \/PRNewswire\/ --AssureRx Health, Inc.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/assurerx-health-launches-personalized-medicine-test-for-adhd.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-44391","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/44391"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=44391"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/44391\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=44391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=44391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=44391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}